Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Abeona Therapeutics (Nasdaq: ABEO) granted equity awards to new non-executive employees under Nasdaq Listing Rule 5635(c)(4) as a material inducement to employment.
On June 30, 2026, five hires received restricted stock awards totaling up to 9,000 shares, vesting in three equal annual installments over three years, subject to continued employment.
Positive
- None.
Negative
- None.
News Market Reaction – ABEO
In the Jul 1 session, ABEO declined 2.10%, reflecting a moderate negative market reaction. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 01 | Employee inducement grants | Neutral | -2.6% | New-hire inducement restricted stock awards granted under Nasdaq Rule 5635(c)(4). |
| May 26 | Investor conferences | Neutral | +0.9% | Management participation in two June 2026 healthcare investor conferences and meetings. |
| May 13 | Quarterly earnings | Positive | +0.5% | Q1 2026 results with higher ZEVASKYN-driven revenue and strong cash balance. |
| May 11 | Commercial expansion | Positive | -0.7% | CHOP activated as sixth Qualified Treatment Center for ZEVASKYN, expanding access. |
| May 04 | Earnings date set | Neutral | +9.6% | Announcement of date and details for upcoming Q1 2026 earnings call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
ABEO has generally traded in line with operational and corporate updates, with one recent divergence on a treatment-center expansion headline.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
restricted stock financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
CLEVELAND, July 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
On June 30, 2026, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to five individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 9,000 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards is scheduled to vest yearly on each anniversary of the Grant Date, such that the shares subject to such restricted stock awards granted to each employee are scheduled to be fully vested on the third anniversary of the Grant Date, in each case, subject to each employee’s continued employment with Abeona on the applicable vesting dates.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features ABO-701 (PSMA-SIR-T™), a potentially first-in-class engineered T-cell therapy targeting PSMA, engineered to overcome the core failures of cell therapies in solid tumors. For more information, visit www.abeonatherapeutics.com.
ZEVASKYN®, Abeona Assist™, Abeona Therapeutics®, and their related logos are trademarks of Abeona Therapeutics Inc.
Contacts: Investor and Media Greg Gin VP, Investor Relations and Corporate Communications Abeona Therapeutics ir@abeonatherapeutics.com Investor Lee M. Stern Meru Advisors lstern@meruadvisors.com